Conventionally, cancer subtyping, prognosis assessment, and therapy choice for cancer patients are based on standard histopathology, such as pathological stainings for KI67, ER, PR and Her2 in the case of breast cancer1, or identifying EGFR, BRAF, and KRAS mutations in colorectal or lung cancer2. This evidence concerns the gene KRAS and cancer.